FATE
Price
$1.05
Change
-$0.05 (-4.55%)
Updated
Jun 27, 02:38 PM (EDT)
Capitalization
126.1M
33 days until earnings call
YMAB
Price
$4.63
Change
-$0.17 (-3.54%)
Updated
Jun 27, 01:27 PM (EDT)
Capitalization
217.42M
41 days until earnings call
Interact to see
Advertisement

FATE vs YMAB

Header iconFATE vs YMAB Comparison
Open Charts FATE vs YMABBanner chart's image
Fate Therapeutics
Price$1.05
Change-$0.05 (-4.55%)
Volume$379
Capitalization126.1M
Y-mAbs Therapeutics
Price$4.63
Change-$0.17 (-3.54%)
Volume$300
Capitalization217.42M
FATE vs YMAB Comparison Chart in %
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FATE vs. YMAB commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and YMAB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (FATE: $1.10 vs. YMAB: $4.80)
Brand notoriety: FATE and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 105% vs. YMAB: 58%
Market capitalization -- FATE: $126.1M vs. YMAB: $217.42M
FATE [@Biotechnology] is valued at $126.1M. YMAB’s [@Biotechnology] market capitalization is $217.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileYMAB’s FA Score has 1 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • YMAB’s FA Score: 1 green, 4 red.
According to our system of comparison, both FATE and YMAB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 3 TA indicator(s) are bullish while YMAB’s TA Score has 5 bullish TA indicator(s).

  • FATE’s TA Score: 3 bullish, 7 bearish.
  • YMAB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, YMAB is a better buy in the short-term than FATE.

Price Growth

FATE (@Biotechnology) experienced а -9.09% price change this week, while YMAB (@Biotechnology) price change was +3.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.95%. For the same industry, the average monthly price growth was +38.50%, and the average quarterly price growth was +16.92%.

Reported Earning Dates

FATE is expected to report earnings on Jul 30, 2025.

YMAB is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+9.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
YMAB($217M) has a higher market cap than FATE($126M). FATE YTD gains are higher at: -33.333 vs. YMAB (-38.697). YMAB has higher annual earnings (EBITDA): -30.39M vs. FATE (-168.28M). FATE has more cash in the bank: 240M vs. YMAB (60.3M). YMAB has less debt than FATE: YMAB (603K) vs FATE (83.3M). YMAB has higher revenues than FATE: YMAB (88.7M) vs FATE (13.3M).
FATEYMABFATE / YMAB
Capitalization126M217M58%
EBITDA-168.28M-30.39M554%
Gain YTD-33.333-38.69786%
P/E RatioN/AN/A-
Revenue13.3M88.7M15%
Total Cash240M60.3M398%
Total Debt83.3M603K13,814%
FUNDAMENTALS RATINGS
FATE vs YMAB: Fundamental Ratings
FATE
YMAB
OUTLOOK RATING
1..100
6572
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
33
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
6163
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (14) in the Biotechnology industry is in the same range as YMAB (33) in the Pharmaceuticals Major industry. This means that FATE’s stock grew similarly to YMAB’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as YMAB (100) in the Pharmaceuticals Major industry. This means that FATE’s stock grew similarly to YMAB’s over the last 12 months.

YMAB's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as FATE (97) in the Biotechnology industry. This means that YMAB’s stock grew similarly to FATE’s over the last 12 months.

FATE's Price Growth Rating (61) in the Biotechnology industry is in the same range as YMAB (63) in the Pharmaceuticals Major industry. This means that FATE’s stock grew similarly to YMAB’s over the last 12 months.

FATE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as YMAB (100) in the Pharmaceuticals Major industry. This means that FATE’s stock grew similarly to YMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FATEYMAB
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 24 days ago
85%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
88%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NAIGX32.81N/A
N/A
Nuveen International Value A
ASVIX9.55N/A
N/A
American Century Small Cap Value Inv
SMFPX10.30N/A
N/A
Westwood Salient MLP & Engy Infras C
IVIPX42.07N/A
N/A
VY® Invesco Equity and Income S2
PISYX11.81N/A
N/A
Victory Pioneer Intrinsic Value Y

YMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with ARWR. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
-2.24%
ARWR - YMAB
53%
Loosely correlated
+2.62%
OCUL - YMAB
51%
Loosely correlated
+2.94%
CRSP - YMAB
50%
Loosely correlated
-0.17%
FATE - YMAB
48%
Loosely correlated
-5.17%
IPSC - YMAB
47%
Loosely correlated
+0.23%
More